Table 1.

Pretreatment Characteristics

	Hormones + RT Whole Pelvis + Boost (n=320)		Hormones + RT Prostate Alone (n=319)		RT Whole Pelvis + Boost + Hormones (n=319)		RT Prostate Alone + Hormones (n=321)
Age (year)
Median	70		70		70		70
Range	46–83		44–87		50–84		45–85
PSA (ng/mL)
Median	23.4		23.3		22.1		23.5
Range	2.9–97.6		2.1–95.1		3.0–98.0		3.9–98.2
T-Stage	n	%	n	%	n	%	n	%
T1c, T2a	74	23	75	24	69	22	68	21
T1b, T2b	32	10	34	11	22	7	41	13
T2c-T4	214	67	210	66	228	71	212	66
PSA
<30	215	67	215	67	213	67	218	68
≥30	105	33	104	33	106	33	103	32
Gleason (Institution)
< 7	85	27	83	26	86	27	86	27
7–10	235	73	236	74	233	73	235	73
Karnofsky status
70	6	2	5	2	5	2	6	2
80	25	8	17	5	22	7	19	6
90	138	43	139	44	132	41	136	42
100	151	47	158	50	160	50	160	50
Race
White	230	72	218	68	222	70	218	68
African American	71	22	88	28	77	24	88	27
Other	19	6	13	4	20	6	15	5
Estimated Risk of Lymph Node Involvement
> 15–35%	239	75	244	76	237	74	244	76
> 35%	81	25	75	24	82	26	77	24